Safety and Efficacy of BL-8040 for the Mobilization of Donor Hematopoietic Stem Cells and Allogeneic Transplantation in Patients With Advanced Hematological Malignancies
Last updated on July 2021Recruitment
- Recruitment Status
- Active, not recruiting
- Estimated Enrollment
- 48
Summary
- Conditions
- Acute Lymphoblastic Leukemia
- Acute Myelogenous Leukemia
- Chronic Myelogenous Leukemia
- Hodgkin Disease
- Hodgkin's Disease
- Multiple Myeloma
- Myelodysplastic Syndrome
- Myeloproliferative Neoplasm
- Non Hodgkin Lymphoma
- Non Hodgkin's Lymphoma
- Type
- Interventional
- Phase
- Phase 2
- Design
- Allocation: Non-RandomizedIntervention Model: Parallel AssignmentMasking: None (Open Label)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 75 years
- Gender
- Both males and females
Description
Not Provided
Not Provided
Tracking Information
- NCT #
- NCT02639559
- Collaborators
- BioLineRx, Ltd.
- Investigators
- Principal Investigator: Geoffrey Uy, M.D. Washington University School of Medicine